AmgenCHIX:AMGD 90 5-Year Yield-on-Cost % is 4.42 as of Jul. 12, 2026, which is 6% above its 10-year median of 4.16. GuruFocus rates CHIX:AMGD with a GF Score™ of 90/100 and a GF Value™ of €325.97 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 516 Drug Manufacturers companies, Amgen ranks better than 67.05% on this metric.
Amgen's yield on cost for the quarter that ended in Mar. 2026 was 4.42.
The historical rank and industry rank for Amgen's 5-Year Yield-on-Cost % or its related term are showing as below:
CHIX:AMGd'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 3.07 Med: 4.16 Max: 5.57
Current: 4.42
During the past 13 years, Amgen's highest Yield on Cost was 5.57. The lowest was 3.07. And the median was 4.16.
CHIX:AMGd's 5-Year Yield-on-Cost % is ranked better than 67.05% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.205
vs CHIX:AMGd: 4.42
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Amgen 5-Year Yield-on-Cost % Related Terms
CHIX:AMGD vs GILD, PFE, BMY: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - General subindustry, Amgen's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amgen 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Amgen's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Amgen's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Amgen is calculated as
Amgen (CHIX:AMGD) has a 5-Year Yield-on-Cost % of 4.42 as of Jul. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Amgen and its competitors. This is near median its historical median of 4.16. Over the past decade, Amgen's 5-Year Yield-on-Cost % has ranged from 3.07 to 5.57. According to the industry distribution chart, Amgen ranks #170 out of 516 companies in the Drug Manufacturers industry, placing it in the top 32.9%.
Is Amgen's 5-Year Yield-on-Cost % too high?
Amgen's current 5-Year Yield-on-Cost % of 4.42 is near median its 10-year median of 4.16. Over the past 10 years, this metric has ranged from a low of 3.07 to a high of 5.57. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.21. Amgen's value of 4.42 is 100.5% above this industry median. Based on the distribution chart, Amgen ranks #170 out of 516 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Amgen has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amgen's 5-Year Yield-on-Cost % compare to GILD and PFE?
According to the Drug Manufacturers industry distribution chart, Amgen ranks #170 out of 516 companies for 5-Year Yield-on-Cost %. This puts Amgen in the upper half of its industry. The industry median 5-Year Yield-on-Cost % is 2.21. Amgen's value of 4.42 is 100.5% above this benchmark. Historically, Amgen's own 5-Year Yield-on-Cost % has ranged from 3.07 to 5.57 over the past decade. While the company's 10-year median is 4.16 vs. the industry median of 2.21, Amgen has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.21, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amgen's current 5-Year Yield-on-Cost % of 4.42 is 100.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Amgen and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amgen's current 5-Year Yield-on-Cost % is 4.42, which is near median its own 10-year median of 4.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amgen stock overvalued right now?
Based on GuruFocus' analysis, Amgen (CHIX:AMGD) is currently considered Modestly Undervalued. The stock's GF Value™ is €325.97, compared to a current price of €285.00 — trading 12.6% below its estimated fair value. The current 5-Year Yield-on-Cost % is 4.42, which is near median its 10-year median of 4.16 and 100.5% above the Drug Manufacturers industry median of 2.21. Amgen's overall GF Score™ is 90/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Amgen (CHIX:AMGD), the current 5-Year Yield-on-Cost % is 4.42 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Amgen (CHIX:AMGD) Overvalued in 2026?
Based on GuruFocus' analysis, Amgen stock appears to be undervalued.
The current stock price of €285.00 is trading 12.6% below its estimated GF Value™ of €325.97.
GuruFocus considers Amgen to be Modestly Undervalued.
Key valuation signals for CHIX:AMGD:
5-Year Yield-on-Cost %: 4.42 (near median its 10-year median of 4.16)
GF Value™: €325.97 vs. price of €285.00 (12.6% below fair value)
Industry Position: 100.5% above the Drug Manufacturers median (#170 of 516)
No single metric tells the full story. See the CHIX:AMGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
90GF Score
Get the complete analysis for CHIX:AMGD
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:AMGD has been successfully added to your 